Suchergebnisse - "Shinoda, Masahiro"

PubPharm (378)

191

Liver Fibrosis Markers Improve Prediction of Outcome in Non‐Acetaminophen‐Associated Acute Liver Failure

enthalten in: Hepatology communications | 2018

von Ugamura, A. | Chu, P. | Nakamoto, N. | +14

192

Successful living donor liver retransplantation for graft failure within 7 days due to acute de novo donor‐specific anti‐human leukocyte antigen antibody‐mediated rejection

enthalten in: Hepatology Research | 2018

von Yamada, Y. | Hoshino, K. | Mori, T. | +17

193

Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation : A Japanese multicenter experience

enthalten in: Clinical transplantation | 2017

von Ikegami, T. | Ueda, Y. | Akamatsu, N. | +20

194

Clinical predictive factors of long-term survival after curative resection of pancreatic cancer : a retrospective study

enthalten in: Cancer medicine | 2017

von Nakano, Y. | Kitago, M. | Shinoda, M. | +7

195

Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation : a Japanese multicenter experience

enthalten in: Journal of gastroenterology | 2017

von Ueda, Y. | Ikegami, T. | Akamatsu, N. | +11

196

Oral administration of cilostazol improves survival rate after rat liver ischemia/reperfusion injury

enthalten in: The Journal of surgical research | 2017

von Fujii, T. | Obara, H. | Matsubara, K. | +11

197

Liver transplantation for hepatobiliary malignancies : a new era of "Transplant Oncology" has begun

enthalten in: Surgery today | 2017

von Hibi, T. | Itano, O. | Shinoda, M. | +1

198

Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience

enthalten in: Journal of gastroenterology | 2017

von Ueda, Y. | Ikegami, T. | Akamatsu, N. | +11

199

Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience

enthalten in: Journal of gastroenterology | 2017

von Ueda, Y. | Ikegami, T. | Akamatsu, N. | +11

200

Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience

enthalten in: Journal of gastroenterology | 2017

von Ueda, Y. | Ikegami, T. | Akamatsu, N. | +11